Helmsley Supports Clinical Trials for Pediatric Crohn’s Disease Therapy

With support from Helmsley’s IBD Program, researchers at The University of North Carolina at Chapel Hill are investigating the potential of combination drug therapy to treat pediatric Crohn’s disease (PCD). PCD is a debilitating chronic condition affecting children under age 17, often resulting in hospitalization and a diminished quality of life.

Anti-Tumor Necrosis Factor (TNF) drugs are currently the most effective treatment for PCD, but these drugs can have serious side effects such as infection, malignancy and recurrence of the disease. Choosing whether or not to use these drugs can be a difficult decision for PCD patients and their families.

Helmsley’s grant builds upon major funding that UNC received from the Patient-Centered Outcomes Research Institute (PCORI) last year to conduct clinical trials and explore the effectiveness of anti-TNF combination therapy. Helmsley support will enhance the impact of the study examining the benefits versus risks and whether combination therapy can lead to improved patient response and remission.